Payment overview · 2025
General Payments
$103.56
5 reported records · 3 companies
Healthcare provider profile · identity verified
James Lee Bockhorst, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TROY, MO · NPI 1053306522
Verified facts
What the public records show
CMS Open Payments records show James Lee Bockhorst, MD received $103.56 in general payments during 2025 across 5 reported records.
Lilly USA, LLC accounted for 43.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 5 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $44.54 | 43.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.41 | 32.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $25.61 | 24.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $103.56 | 5 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.54 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $25.61 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.10 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 66 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
100 | 30 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
66 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
112 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 630 | 195 |
| Amlodipine Besylate | Amlodipine Besylate | 481 | 135 |
| Lisinopril | Lisinopril | 456 | 137 |
| Levothyroxine Sodium | Levothyroxine Sodium | 448 | 123 |
| Metoprolol Succinate | Metoprolol Succinate | 341 | 91 |
| Pantoprazole Sodium | Pantoprazole Sodium | 333 | 100 |
| Losartan Potassium | Losartan Potassium | 320 | 88 |
| Alprazolam | Alprazolam | 299 | 49 |
| Omeprazole | Omeprazole | 289 | 84 |
| Tramadol Hcl | Tramadol Hcl | 283 | 66 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 248 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 75 |
| Gabapentin | Gabapentin | 238 | 73 |
| Furosemide | Furosemide | 235 | 70 |
| Metoprolol Tartrate | Metoprolol Tartrate | 216 | 55 |
| Simvastatin | Simvastatin | 194 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 184 | 44 |
| Eliquis | Apixaban | 181 | 44 |
| Metformin Hcl | Metformin Hcl | 176 | 51 |
| Meloxicam | Meloxicam | 173 | 51 |
| Potassium Chloride | Potassium Chloride | 167 | 52 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 162 | 66 |
| Trazodone Hcl | Trazodone Hcl | 162 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 153 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 147 | 47 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 139 | 41 |
| Pravastatin Sodium | Pravastatin Sodium | 137 | 39 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 136 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 128 | 35 |
| Carvedilol | Carvedilol | 118 | 35 |
| Glimepiride | Glimepiride | 116 | 36 |
| Trulicity | Dulaglutide | 112 | 19 |
| Metformin Hcl Er | Metformin Hcl | 111 | 38 |
| Alendronate Sodium | Alendronate Sodium | 103 | 34 |
| Warfarin Sodium | Warfarin Sodium | 103 | 24 |
| Sertraline Hcl | Sertraline Hcl | 101 | 28 |
| Jardiance | Empagliflozin | 100 | 30 |
| Finasteride | Finasteride | 99 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 29 |
| Allopurinol | Allopurinol | 85 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 25 |
| Montelukast Sodium | Montelukast Sodium | 83 | 27 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 20 |
| Lorazepam | Lorazepam | 80 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 79 | 15 |
| Donepezil Hcl | Donepezil Hcl | 77 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 20 |
| Ondansetron Odt | Ondansetron | 72 | 23 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 71 | 15 |
| Spironolactone | Spironolactone | 71 | 25 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 69 | 69 |
| Clonazepam | Clonazepam | 68 | 17 |
| Mounjaro | Tirzepatide | 66 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 64 | 21 |
| Xarelto | Rivaroxaban | 64 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 63 | 16 |
| Lovastatin | Lovastatin | 60 | 18 |
| Methylprednisolone | Methylprednisolone | 56 | 34 |
| Famotidine | Famotidine | 55 | 18 |
| Ozempic | Semaglutide | 55 | 16 |
| Prednisone | Prednisone | 55 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 55 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 42 |
| Pregabalin | Pregabalin | 52 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 51 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 51 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 50 | 38 |
| Temazepam | Temazepam | 50 | suppressed |
| Nystatin | Nystatin | 49 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | 14 |
| Memantine Hcl | Memantine Hcl | 47 | 14 |
| Diazepam | Diazepam | 44 | 15 |
| Glipizide Er | Glipizide | 42 | 11 |
| Januvia | Sitagliptin Phosphate | 42 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 42 | 13 |
| Benazepril Hcl | Benazepril Hcl | 41 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 39 | 15 |
| Cefuroxime | Cefuroxime Axetil | 39 | 37 |
| Synthroid | Levothyroxine Sodium | 39 | 12 |
| Ezetimibe | Ezetimibe | 38 | suppressed |
| Aripiprazole | Aripiprazole | 37 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 36 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 34 | suppressed |
| Celecoxib | Celecoxib | 33 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 32 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 31 | suppressed |
| Phenobarbital | Phenobarbital | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Topiramate | Topiramate | 30 | suppressed |
| Baclofen | Baclofen | 29 | suppressed |
| Atenolol | Atenolol | 28 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 26 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Azithromycin | Azithromycin | 25 | 24 |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 24 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 24 | suppressed |
| Valsartan | Valsartan | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 22 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 22 | suppressed |
| Myrbetriq | Mirabegron | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Levetiracetam | Levetiracetam | 21 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 21 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 20 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 15 |
| Novolog Flexpen | Insulin Aspart | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 19 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 17 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Febuxostat | Febuxostat | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 14 | suppressed |
| Probenecid | Probenecid | 14 | suppressed |
| Torsemide | Torsemide | 14 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 12 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Concerta | Methylphenidate Hcl | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 11 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $103.56 · 5 records | Lilly USA, LLC | Dexcom G6 Transmitter, MOUNJARO, Ozempic, Wegovy, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error